Axovant Doses First Patient in Parkinson’s Trial

The drug, AXO-Lenti-PD, was well tolerated and the patient was able to leave the hospital as expected with no side...

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD

Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and neuromuscular diseases, announced dosing of the first patient...

Axovant Licenses Investigational Gene Therapy for Parkinson’s Disease from Oxford BioMedica and Announces Key Leadership Team Addition

Axovant Sciences (NASDAQ:AXON) announced that it has licensed the exclusive worldwide rights to develop and commercialize OXB-102, now AXO-Lenti-PD, from...